Relay Therapeutics, Inc. (RLAY) Tops Q4 EPS by 14c

Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q4 EPS of ($0.56), $0.14 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $250 thousand versus the consensus estimate of $233.33 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.

You May Also Be Interested In

• Relay Therapeutics (RLAY) PT Raised to $29 at H.C. Wainwright
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'